日本 RNA 疗法市场评估：依类型、产品、适应症、最终用户、地区、机会和预测（2018年度-2032年度）

日本 RNA 治疗市场规模预计将从2024年度的14.0391亿美元增至2032年度的31.2358亿美元，预计在2025年度至2032年度的预测期内年复合成长率为 10.52%。各大学不断增加的研究活动支持市场成长，包括推出支持政策、增加专利发放以及加强市场与区域公司之间的合作。随着日本老化社会迅速扩大，医疗进步和健康问题意识不断增强，导致新技术的采用。根据世界经济论坛估计，日本超过十分之一的人年龄超过80岁。

日本加强个人化医疗的开发和可用性也推动了日本 RNA 治疗市场的发展。2024年 7月，LSI Medience Corporation 和癌症基因组分析领先公司之一 ACT Genomics Co. Ltd. 宣布，双方已签署关于日本市场合作的谅解备忘录。此次合作预计将为日本个人化医疗的发展做出巨大贡献。最初，它将致力于将基因组分析整合到研究活动中，为研究人员提供个人化资讯。此类合作研究预计将推动日本 RNA 治疗市场的发展。

此外，日本慢性病患者数量的增加也支持了市场的扩张。由于RNA结合蛋白通常结合多个转录物，因此靶向核糖核蛋白（RNP）可以帮助改善癌症和自体免疫疾病，其中RNA结合蛋白在不同转录物中发挥复杂的作用，有可能为系统性疾病（例如，癌症和自体免疫疾病）提供有效的治疗解决方案。

此外，mRNA疫苗的日益普及也推动了日本对 RNA 疗法的需求。在过去的几年里，mRNA疫苗透过确保针对传染病的标靶疫苗的快速开发而显示出巨大的潜力。此外，其模组化特性使其能够透过简单地改变编码任何抗原的mRNA 序列来轻鬆适应不同的病原体。人们越来越认识到 mRNA 疫苗带来的好处，加强了对研究活动的需求和投资，对市场扩张产生了积极影响。

本报告研究和分析了日本 RNA 治疗市场，提供市场规模和预测、市场动态以及主要公司的状况。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章 日本RNA治疗市场展望（2018年度-2032年度）

• 市场规模分析与预测
  • 金额
  • 数量
• 市场占有率分析与预测
  • 依类型
  • 依产品
  • 依适应症
  • 依最终用户
  • 依地区
  • 市场占有率分析：依公司（价值）（前5名公司及其他 -2024年度）
• 市场地图分析（2024年）
  • 依类型
  • 依产品
  • 依适应症
  • 依最终用户
  • 依地区

第5章 供需分析

第6章 进出口分析

第7章 价值链分析

第8章 波特五力分析

第9章 PESTLE分析

第10章 价格分析

第11章 市场动态

• 市场驱动因素
• 市场挑战

第12章 市场趋势与发展

第13章 监理架构与创新

• 临床试验
• 监理机关的核准

第14章 专利状况

第15章 个案研究

第16章 竞争态势

• 前5名市场领导者的竞争矩阵
• 前5名的公司的SWOT 分析
• 主要企业状况
  • Pfizer Inc.
  • Moderna, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Biogen Inc.
  • NS Pharma, Inc.
  • Novartis Pharmaceuticals Corporation
  • Jazz Pharmaceuticals Plc
  • Arcturus Therapeutics Holdings Inc.

第17章 策略建议

第18章 关于本公司，免责声明

Japan RNA therapeutics market is projected to witness a CAGR of 10.52% during the forecast period FY2025-FY2032, growing from USD 1,403.91 million in FY2024 to USD 3,123.58 million in FY2032. Rising research activities by various universities support the market's growth, the introduction of supportive government measures, increasing issuance of patents, and rising collaborations between market players and regional companies. Due to the rapid expansion of the aging population in Japan, the country is becoming more aware of medical developments and health challenges and adopting novel technologies. According to estimates from the World Economic Forum, over 1 in 10 people in Japan are 80 or older.

The increasing efforts to bolster the development and availability of personalized medicines in the country are also propelling the Japan RNA therapeutics market. In July 2024, LSI Medience Corporation and ACT Genomics Co. Ltd., one of the leaders in cancer genomic profiling, announced that they had signed a Memorandum of Understanding (MoU) to collaborate in the Japanese market. The partnership is expected to significantly contribute to the advancements of personalized medicines in Japan. It is initially going to focus on the integration of genomic profiling in research practices and provide researchers with personalized information. Such collaborations are expected to propel the Japan RNA therapeutics market.

Additionally, the rising cases of chronic diseases in the country are also supporting the market's expansion. The RNA-binding proteins usually bind with multiple transcripts, thus targeting ribonucleoproteins (RNPs) hold promise for delivering effective treatment solutions for systemic diseases including cancer and autoimmune disorders, among others, where an intricate role is played by RNA-binding proteins across diverse transcripts.

Furthermore, the growing popularity of messenger RNA (mRNA) vaccines is also bolstering the demand for Japan RNA therapeutics. Over the past few years, mRNA vaccines have shown significant potential by ensuring the rapid development of targeted vaccines for infectious diseases. Furthermore, their modular nature allows them to adapt easily to different pathogens by simply conducting alterations in the mRNA sequence that encodes the desired antigen. The growing awareness about such advantages associated with mRNA vaccines is bolstering their demand and investments towards research activities, positively influencing the market's expansion.

Supportive Government Measures Boost Market Expansion

The growing efforts of the government of Japan to support the development and availability of RNA therapeutics in the country are propelling the market's expansion. The government also provides grants to boost mRNA therapeutics and vaccine production. In August 2023, the government awarded USD 115 million in two separate grants to ARCALIS Inc., the manufacturing joint venture of Arcturus Therapeutics Holdings Inc. in Japan. The grants would be used to fund the mRNA drug product operations and the production of mRNA drug substances by allowing the purchase of capital equipment to support current Good Manufacturing Practices (cGMP) and the construction of a factory. Such efforts are expected to provide lucrative growth opportunities for the market in the coming years and bolster the availability of therapeutics that offer greater durability and high levels of efficacy.

Rising Issuance of Patents Supports Market Growth

The increasing issue of patents for nucleic acid extraction technologies for various companies in Japan is also expected to bolster the growth of the market. In March 2023, BioEcho Life Sciences GmbH, one of the leading biotechnology companies announced the issuance of two new patents by the Japan Patent Office, covering their EchoLUTION technology for extraction of nucleic acids. The EchoLUTION technology allows for the extraction of RNA and DNA in a single centrifugation step, resulting in the availability of inhibitor-free and high-quality RNA and DNA that is ready for downstream applications. Such patents aid in strengthening a company's intellectual property portfolio and foster innovations to ensure the availability of novel technologies. The issuance is also expected to transform different processes in biopharmaceutical research, molecular diagnostics, academics, and animal and plant breeding.

mRNA Therapeutics Account for Major Market Share

The rapid advancements in molecular medicine and biotechnology have bolstered the therapeutic applications of mRNA. mRNA is transcribed from a DNA strand, carrying coding information necessary for the synthesis of proteins so that it can be further processed and transcribed into functional proteins. The rising research activities by leading universities in the country is also expected to aid the segment's expansion. In March 2024, a team of researchers from the Tokyo Medical and Dental University (TMDU) announced that they had successfully developed a new method for chemically modifying engineered mRNA molecules, advancing mRNA therapeutic technologies and allowing greater control of the biological functions of RNA molecules. The mRNA technology holds significant potential for developing novel cancer vaccines and treatments and for treating a wide range of diseases that had earlier been deemed incurable. The development of such innovative techniques is expected to ensure significant advancements in the therapeutic applications of mRNA polyplexes.

Vaccine Segment Holds Major Market Share

mRNA vaccines introduce a piece of mRNA corresponding to the viral protein. The immune system produces antibodies as it recognizes the protein as a foreign substance, as part of a normal immune response. Antibodies aid in protecting the host against infections by recognizing individual pathogens and viruses and marking them for destruction. Upon production, the antibodies stay in the body even after the pathogen has been eliminated from the body, allowing the immune system to respond quickly in case of future exposures.

The rising approvals for RNA vaccines in Japan are expected to provide lucrative growth opportunities to the market in the coming years. In November 2023, the Ministry of Health, Labor and Welfare of Japan approved the first self-amplifying mRNA vaccine that Arcturus Therapeutics Holdings Inc. and CSL developed. Such approvals are expected to influence the market's expansion in the coming years positively.

Future Market Scenario (FY2025-FY2032F)

As per the Japan RNA therapeutics market analysis, the evolving requirements of the patient population in Japan due to the country's rapid aging and rising cases of chronic diseases are expected to bolster the demand for RNA therapeutics in Japan. The proven applications of RNAi in rare diseases, along with new developments that aid in targeting cancer, are also expected to positively influence the market's expansion.

Additionally, various research studies are also underway to evaluate the working and efficacy of different RNA therapeutics. For instance, Gilead Sciences, Inc. is conducting an interventional study to evaluate the antiviral activity of lenacapavir in patients with human immunodeficiency virus (HIV) (PWH) with multi-drug resistance. The study is expected to conclude in January 2027. Such studies are expected to provide lucrative growth opportunities for the market.

Key Players Landscape and Outlook

Increasing collaborations between leading market players and regional companies are expected to provide lucrative growth opportunities for the market. In July 2024, Mitsubishi Tanabe Pharma Corporation and Moderna, Inc. announced that they have entered into an agreement to promote latter's mRNA respiratory vaccine portfolio in the country. Under the agreement, both companies are going to engage in various activities to ensure the availability of Moderna's mRNA portfolio and make an impact on Japan's public health. The initial term of the agreement was listed on March 31, 2029. Such partnerships are expected to contribute towards enhancing the country's pharmaceutical sector and public health.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan RNA Therapeutics Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. RNA Interference (RNAi) Therapeutics
    • 4.2.1.2. mRNA Therapeutics
    • 4.2.1.3. Antisense Oligonucleotide (ASO)Therapeutics
    • 4.2.1.4. Others
  • 4.2.2. By Product
    • 4.2.2.1. Vaccines
    • 4.2.2.2. Drugs
  • 4.2.3. By Indication
    • 4.2.3.1. Rare Genetic Diseases/Hereditary Diseases
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Academic Research Centers
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Product
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top Market Players
  • 16.3.1. Pfizer Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Moderna, Inc.
  • 16.3.3. Alnylam Pharmaceuticals, Inc.
  • 16.3.4. Biogen Inc.
  • 16.3.5. NS Pharma, Inc.
  • 16.3.6. Novartis Pharmaceuticals Corporation
  • 16.3.7. Jazz Pharmaceuticals Plc
  • 16.3.8. Arcturus Therapeutics Holdings Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan RNA Therapeutics Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. Japan RNA Therapeutics Market, By Volume, In Thousand Doses, FY2018-FY2032F
• Figure 3. Japan RNA Therapeutics Market Share (%), By Type, FY2018-FY2032F
• Figure 4. Japan RNA Therapeutics Market Share (%), By Product, FY2018-FY2032F
• Figure 5. Japan RNA Therapeutics Market Share (%), By Indication, FY2018-FY2032F
• Figure 6. Japan RNA Therapeutics Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. Japan RNA Therapeutics Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Indication Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024